Restore Mind Medicine

Commitment for Judicious Use of Shareholder Capital OR See [21] IHH HIIHI HIIHH MindMed should be judicious about further equity issuances to preserve value for existing investors. We want to attract long term investors who believe in the Company and its prospects, not because they are receiving a deal at 30% of market price. We would not look to raise additional equity to engage in dilution until after the Phase III trial has enrolled over 50 patients. We believe MindMed should utilize convertible preferred stock to take advantage of the Company's high implied volatility to reduce financing costs and ensure that dilution does not occur until MindMed's share price appreciates from the time of the offering. Numerous biotechnology companies have employed this strategy including MindMed's competitor Compass Pathways. 78

View entire presentation